Vor Biopharma shares surge 20.14% intraday after announcing private placement and forming bullish rounding bottom pattern.

Vor Biopharma surged 20.14% intraday after announcing the pricing of a private placement offering 5.4 million shares at $14.05, signaling a capital-raising effort that boosted investor confidence. This development came alongside Wedbush upgrading its price target from $9 to $15, reinforcing potential value despite a neutral rating. The stock also showed technical signs of a rounding bottom pattern with strong volume and momentum metrics, suggesting institutional accumulation. However, the lack of major clinical or regulatory news meant the rally was largely driven by capital structure activity and improving technical indicators amid a bearish biotech sector backdrop.